3Advanced precancerous lesions in the lower oesophageal mucosa: High-grade dysplasia and intramucosal carcinoma in Barrett's oesophagus
Introduction
During recent decades, the incidence of oesophageal adenocarcinoma has risen dramatically in most Western countries. This tumour is now the most common type of oesophageal cancer in the United States and in parts of Western Europe [1], [2]. The prognosis of oesophageal adenocarcinoma remains poor, with a five-year survival less than 15 percent [3]. Barrett's oesophagus (BO) is recognized as the precursor of almost all cases of oesophageal adenocarcinoma [4]. Two systematic reviews and meta-analyses of 47 and 51 studies found an average cancer incidence of 0.6% per year in patients with BO [5], [6]; however, this risk may be lower than it was estimated previously: in a recent population-based study in Denmark, the absolute annual risk of cancer was only 0.12% [7]. Nevertheless, BO surveillance has been recommended to detect dysplasia and early carcinoma. The diagnosis of these early neoplastic lesions has been very much improved with recent innovations in endoscopic techniques, and their treatment now relies on non-surgical procedures in most cases.
Section snippets
Barrett's oesophagus, Barrett's dysplasia and Barrett's carcinoma: definition and main molecular changes
BO is defined by the American Gastroenterological Association (AGA) as ‘the condition in which any extent of metaplastic columnar epithelium that predisposes to cancer development replaces the stratified epithelium that normally lines the distal oesophagus’ [8]. Whether or not this definition implies the presence of intestinal-type columnar epithelium with goblet cells is still a matter of debate, which will not be discussed in detail in this article (for review, ref. [9], [10]). The
Pathological features of high-grade dysplasia and intramucosal carcinoma
HGD is characterized by marked cellular atypia and complex architectural changes. Adenomatous (also called intestinal) dysplasia is the most frequent histological subtype, but two other types can be observed: non-adenomatous or foveolar type dysplasia and basal crypt dysplasia [16], [17]. IMC invades the lamina propria, and is defined primarily by its architectural properties.
Cancer risk in patients with dysplasia in BO
Although it is well established that patients with dysplasia in BO have an increased risk of cancer, the exact risk of progression to carcinoma is difficult to establish with certainty. One of the reasons of the variable results published in the literature is the high number of prevalent carcinomas missed on the initial endoscopy, resulting in some studies in a risk of progression from HGD to carcinoma as high as 90%. In a meta-analysis that excluded prevalent carcinomas, the incidence of
Diagnostic criteria of BO
The diagnosis of BO is suspected at endoscopy and confirmed with histology [39]. Indeed, endoscopic suspicion of BO appears like an abnormal salmon-coloured mucosa in the lower oesophagus, above the top of gastric folds, replacing the normal pale pink-coloured oesophageal mucosa. At this stage, the term ‘endoscopic suspicion of oesophageal metaplasia’ (ESEM) should be used by the endoscopist in the endoscopy report, and biopsies should be taken in order to confirm the presence of intestinal
Management of high-grade dysplasia and early carcinoma in Barrett's oesophagus
Until recently, surgical resection was the treatment of choice for early stage lesions in BO, but this paradigm is currently challenged by interventional endoscopy [55]. Oesophagectomy is associated with significant mortality and morbidity even when surgery is performed in high volume expert centres. Operative mortality rate for oesophagectomy for HGD and early adenocarcinoma ranges from 0% to 4%, with an overall operative 30-day mortality rate of approximately 2% [56]. The management of early
Conflict of interest
None.
References (72)
- et al.
The columnar-lined esophagus intestinal metaplasia, and Norman Barrett
Gastroenterology
(1996) - et al.
Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis
Clin Gastroenterol Hepatol
(2010) - et al.
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus
Gastroenterology
(2010) - et al.
Goblet cells in Barrett's oesophagus: cancer precursor, risk marker, or irrelevance?
Diagn Histopathol
(2012) - et al.
Molecular biology of Barrett's cancer
Best Pract Res Clin Gastroenterol
(2006) - et al.
Foveolar type dysplasia in Barrett esophagus
Mod Pathol
(2010) - et al.
Grading of gastric foveolar-type dysplasia in Barrett's oesophagus
Mod Pathol
(2010) - et al.
Expression of α-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus
Mod Pathol
(2008) - et al.
Barrett's esophagus. Practical issues for daily routine diagnosis
Pathol Res Pract
(2012) - et al.
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation
Hum Pathol
(2001)
Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis
Gastrointest Endosc
Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma
Gastroenterology
The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria
Gastroenterology
Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus
Gastrointest Endosc
Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus
Lancet
Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus
Gastrointest Endosc
Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus
Gastroenterology
Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett's esophagus by using narrow band imaging
Gastrointest Endosc
Systematic review of narrow band imaging for the detection and differentiation of abnormalities in the esophagus and stomach (with video)
Gastrointest Endosc
Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus
Gastroenterology
Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus
Clin Gastroenterol Hepatol
Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial
Gastrointest Endosc
Endoscopic versus surgical therapy for early cancer in Barrett's esophagus
Gastrointest Endosc
EMR for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy
Gastrointest Endosc
Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer)
Gastrointest Endosc
Clinical impact of endoscopic submucosal dissection for superficial adenocarcinoma located at the esophagogastric junction
Gastrointest Endosc
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia
Gastrointest Endosc
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus
Gastroenterology
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process
Gastroenterology
Esophageal adenocarcinoma incidence: are we reaching the peak?
Cancer Epidemiol Biomarkers Prev
Oesophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west
Gastroenterology
Gastro-oesophageal cancer: death at the junction
BMJ
The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis
Am J Epidemiol
Incidence of adenocarcinoma among patients with Barrett's esophagus
N Engl J Med
Definition of Barrett's esophagus: time for a rethink – is intestinal metaplasia dead?
Am J Gastroenterol
Premalignant lesions of the digestive system
Cited by (13)
New Indications for Endoscopic Radiofrequency Ablation
2018, Clinical Gastroenterology and HepatologyRadiofrequency ablation is a treatment option for early stages of verrucous esophageal carcinoma
2016, VideoGIECitation Excerpt :Those are also the main reasons why initial neoadjuvant therapy was not provided to our patient. Endoscopic radiofrequency ablation is a well-validated therapy for dysplastic Barrett's disease, and it also has become increasingly accepted for early squamous cell carcinoma of the esophagus.2,7,8 In our case, relapsing verrucous carcinoma involved the whole circumference of the remaining esophagus.
Safety and feasibility of volumetric laser endomicroscopy in patients with Barrett's esophagus (with videos)
2015, Gastrointestinal EndoscopyAdvanced precancerous lesions within the GI tract: The molecular background
2013, Best Practice and Research: Clinical GastroenterologyCitation Excerpt :Adenocarcinoma (mainly arising within Barrett's mucosa), and squamous cell carcinoma are the two main cancer histotypes arising from the oesophageal mucosa [40]. In the last 25 years, definite evidence has been provided that both cancers are the final event in a progressive dedifferentiation of native oesophageal mucosa (precancerous lesions) associated with a broad spectrum of genotypic changes [11,13,29,37,41,42]. Barrett's metaplastic glands are considered the ‘carcinogenic field’ in which dysplastic lesions may develop [43,44].
Screening for preneoplastic lesions of the upper gastrointestinal tract
2023, Revue Medicale SuisseDeep learning for diagnosis of precancerous lesions in upper gastrointestinal endoscopy: A review
2021, World Journal of Gastroenterology